PreModificationWarrantsMember
AwardType [Axis]
PostModificationWarrantsMember
ShareBasedCompensationWarrantsOneMember
Range [Axis]
ShareBasedCompensationWarrantsTwoMember
ShareBasedCompensationWarrantsFourMember
ShareBasedCompensationWarrantsFiveMember
ShareBasedCompensationWarrantsSixMember
ShareBasedCompensationWarrantsSevenMember
ShareBasedCompensationWarrantsEightMember
ShareBasedCompensationWarrantsNineMember
ShareBasedCompensationWarrantsTenMember
ShareBasedCompensationWarrantsElevenMember
ShareBasedCompensationWarrantsTwelveMember
February2012ConvertibleNotes12PercentMember
Debt Instrument [Axis]
InvestorRelationServicesMember
Equity Components [Axis]
InvestorRelationsAndPublicCompanyServicesMember
AdditionalInvestorRelationsServicesMember
WarrantModificationsMember
ForegoingExercisesMember
Platinum [Member]
Series A Preferred
Statement Class Of Stock [Axis]
QualifiedFinancingMember
LegalEntityAxis
LegalEntity [Axis]
Pre-Modification [Member]
Short-term Debt, Type [Axis]
Post-Modification [Member]
CatoBioVentures [Member]
NotesPayableToRelatedParties [Member]
Related Party [Axis]
CurrentPortionFour [Member]
Maximum [Member]
Income Statement Location [Axis]
Minimum [Member]
Stock Incentive Plan [Member]
Antidilutive Securities [Axis]
Note 1 [Member]
Note 2 [Member]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Hierarchy [Axis]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Senior Note1 [Member]
Senior Note 2 [Member]
Senior Note 3 [Member]
Senior Note 4 [Member]
Senior Note 5 [Member]
Senior NonCurrent [Member]
Seven% Note [Member]
Seven % Current [Member]
Seven % Noncurrent [Member]
M F Note B [Member]
M F Note A [Member]
BurrPilgerMayer [Member]
Desjardins [Member]
McCarthyTetrault [Member]
UniversityHealthNote1 [Member]
Service Provider Notes Total [Member]
Service Providers Current [Member]
Service Providers Noncurrent [Member]
Insurance Company [Member]
Vendor [Member]
Vendor Current [Member]
TenPercentCurrent [Member]
Unrelated Parties [Member]
Unrelated Parties Current [Member]
Unrelated Parties Noncurrent [Member]
Cato Note 1 [Member]
Cato Note 2 [Member]
Related Parties Aggregate [Member]
Related Parties Current [Member]
Related Parties Noncurrent [Member]
Related Parties After Discount [Member]
Service Providers After Discount [Member]
Senior Note Total [Member]
Senior Note Noncurrent [Member]
SeniorNote 7 [Member]
Ten% Total [Member]
Ten % Noncurrent [Member]
MF Note A [Member]
Service Providers Total [Member]
MF Note B [Member]
Univ Health Note [Member]
Service Note Current [Member]
Service Notes Noncurrent [Member]
TenPercenNoncurrent [Member]
Senior Notes Total [Member]
Service Providers Aggregate [Member]
Related Parties [Member]
Warrant 1 [Member]
Class of Warrant or Right [Axis]
Warrant 2 [Member]
Warrant 3 [Member]
Warrant 4 [Member]
Warrant 5 [Member]
Warrant 6 [Member]
Warrant 7 [Member]
Warrant 8 [Member]
Warrant 9 [Member]
Warrant 10 [Member]
Warrant 11 [Member]
Warrant 12 [Member]
Warrant 13 [Member]
Warrant Modification [Member]
Equity Method Investee, Name [Axis]
Platinum Modifications [Member]
2013 Private Placement [Member]
Note 3 [Member]
Note 4 [Member]
US NIH [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
UHN [Member]
Cato [Member]
CBV Note [Member]
CRL Note [Member]
Officer [Member]
Subsequent Event [Member]
Subsequent Event Type [Axis]
Warrant [Member]
Senior Note 6 [Member]
Ten Percent Note [Member]
Autilion AG [Member]
Platinum Mod Series A [Member]
Range High [Member]
Range Low [Member]
ConvertibleNoteJuly [Member]
PreModification 2 [Member]
PostModification 2 [Member]
PreModification 3 [Member]
PostModification 3 [Member]
Preferred Stock [Member]
Common Stock
Additional Paid-In Capital
Treasury Stock
Notes Receivable for Sale of Stock
Deficit Accumulated During the Development Stage
PlatinumExchangeNotes [Member]
PlatinumJuly2013Note [Member]
PrivatePlacementNotes [Member]
AntidilutiveNotes1 [Member]
AntidilutiveNotes2 [Member]
AntidilutiveNotes3 [Member]
AV 101 [Member]
Significant Acquisitions and Disposals by Transaction [Axis]
DiscountNote1 [Member]
Schedule of Receivables with Imputed Interest, Name of Receivable with Imputed Interest [Axis]
DiscountNote2 [Member]
DiscountNote3 [Member]
DiscountNote4 [Member]
DiscountNote5 [Member]
DiscountNote6 [Member]
PreModification4 [Member]
PostModification4 [Member]
PreModification5Member
PostModification5Member
Stock Plan 2008 [Member]
Share Based Compensation [Axis]
Stock Plan 1999 [Member]
Plan 401k [Member]
$0.40 [Member]
Exercise Price Range [Axis]
$0.50 [Member]
$0.72 - $1.80 [Member]
$0.72 - $1.80 [Member]
Series B Preferred
Series B-1 Preferred
Series C Preferred
Preferred Stock
Notes Receivable from Sale of Stock
Senior Note 6 [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Is Entity a Well-known Seasoned Issuer?
Is Entity a Voluntary Filer?
Is Entity's Reporting Status Current?
Entity Filer Category
Entity Public Float
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash and cash equivalents
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Security deposits and other assets
Total assets
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable
Accrued expenses
Advance from officer
Current portion of notes payable and accrued interest
Current portion of notes payable to related parties and accrued interest
Convertible promissory notes and accrued interest, net of discount of $697,400 at March 31, 2014
Capital lease obligations
Total current liabilities
Non-current liabilities:
Senior secured convertible promissory notes, net of discount of $2,085,900 at March 31, 2014 and $1,963,100 at March 31, 2013 and accrued interest
Notes payable, net of discount of $848,100 at March 31, 2014 and $1,142,600 at March 31, 2013 and accrued interest
Notes payable to related parties, net of discount of $103,200 at March 31, 2014 and $147,200 at March 31, 2013 and accrued interest
Warrant liability
Deferred rent liability
Capital lease obligations
Total non-current liabilities
Total liabilities
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $0.001 par value; 10,000,000 shares, including 500,000 Series A shares, authorized at March 31, 2014 and 2013; 500,000 Series A shares issued and outstanding at March 31, 2014 and 2013, respectively
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2014 and 2013; 26,200,185 and 23,480,169 shares issued at March 31, 2014 and 2013, respectively
Additional paid-in capital
Treasury stock, at cost, 2,713,308 shares of common stock held at March 31, 2014 and 2013
Notes receivable from sale of common stock
Deficit accumulated during development stage
Total stockholders' deficit
Total liabilities and stockholders' deficit
Convertible promissory notes and accrued interest, net of discount
Senior secured convertible promissory notes, net of discount
Notes payable, net of discount
Notes payable to related parties, net of discount
Stockholders deficit:
Preferred Stock, par value
Preferred Stock, Authorized
PreferredStockSeriesASharesIssued
PreferredStockSeriesASharesOutstanding
Common Stock, Par Value Par Share
Common Stock, Shares Authorized
Common Stock, Shares, Issued
Treasury Stock, Shares
Income Statement [Abstract]
Revenues:
Grant revenue
Collaboration revenue
Other
Total revenues
Operating expenses:
Research and development
Acquired in-process research and development
General and administrative
Total operating expenses
Loss from operations
Other expenses, net:
Interest expense, net
Change in warrant and put and note extension option liabilities
Loss on early extinguishment of debt
Other income
Loss before income taxes
Income taxes
Net loss
Deemed dividend on Series A Preferred stock
Net loss attributable to common stockholders
Basic net loss attributable to common stockholders per common share
Diluted net loss attributable to common stockholders per common share
Weighted average shares used in computing basic net loss attributable to common stockholders per common share
Weighted average shares used in computing diluted net loss attributable to common stockholders per common share
Comprehensive loss
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Amortization of discounts on convertible and promissory notes
Change in warrant and put and note term extension option liabilities
Stock-based compensation
Expense related to modification of warrants
Non-cash rent and relocation expense
Interest income on note receivable for stock purchase
Fair value of common stock granted for services following the Merger
Fair value of warrants granted for services and interest following the Merger
Gain on currency fluctuation
Fair value of additional warrants granted pursuant to exercises of modified warrants
Loss on settlements of accounts payable
Loss on early extinguishment of debt
Fair value of Series C preferred stock, common stock, and warrants granted for services prior to the Merger
Fair value of common stock issued for note term modification
Consulting services by related parties settled by issuing promissory notes
Gain on sale of assets
Changes in operating assets and liabilities:
Unbilled contract payments receivable
Prepaid expenses and other current assets
Security deposits and other assets
Accounts payable and accrued expenses, including accrued interest
Deferred revenues
Net cash used in operating activities
Cash flows from investing activities:
Purchases of equipment, net
Net cash used in investing activities
Cash flows from financing activities:
Net proceeds from issuance of common stock and warrants, including Units
Proceeds from exercise of modified warrants
Proceeds from issuance of Platinum notes and warrants
Advance from officer
Proceeds from issuance of notes under line of credit
Proceeds from issuance of 7% note payable to founding stockholder
Net proceeds from issuance of 7% convertible notes
Net proceeds from issuance of 10% convertible notes and warrants
Net proceeds from issuance of preferred stock and warrants
Net proceeds from issuance of notes and warrants from 2006 to 2010
Net proceeds from issuance of February 2012 12% convertible notes and warrants
Repayment of capital lease obligations
Repayment of notes
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow activities:
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of noncash activities:
Forgiveness of accrued compensation and accrued interest payable to officers transferred to equity
Exercise of warrants and options in exchange for debt cancellation
Settlement of accrued and prepaid interest by issuance of Series C Preferred Stock
Conversion of 10% notes payable, net of discount, and related accrued interest of $408,600 into Series C Preferred stock
Issuance of Series B-1 Preferred stock for acquired in-process research and development
Conversion of 7% notes payable, net of discount, and related accrued interest of $3,800 into Series B Preferred stock
Conversion of accounts payable into convertible promissory notes
Conversion of accounts payable into note payable
Conversion of accounts payable into common stock
Conversion of accrued interest on convertible promissory notes into common stock
Notes receivable from sale of common stock to related parties upon exercise of options and warrants
Capital lease obligations
Recognition of put option and note term extension option liabilities upon issuance of Original Platinum Notes
Incremental fair value of put option and note term extension option liabilities from debt modifications
Incremental fair value of note conversion option from debt modification
Incremental fair value of warrant from debt modifications
Recognition of warrant liability upon adoption of new accounting standard
Fair value of warrants issued with August 2010 short term notes
Note discount upon issuance of August 2010 short term notes
Fair value of warrants issued with February 2012 12 % convertible notes
Note discount upon issuance of February 2012 12% convertible notes
Conversion of 2006/2007 and 2008/2010 Notes into Units, including accrued interest of $1,365,600
Conversion of all series of pre-Merger preferred stock into Units
Conversion of 2011 Platinum Note into Series A Preferred Stock, including accrued interest of $611,100 and conversion premium
Conversion of 7% note payable and accrued interest of $11,500 into common stock and warrants
Conversion of accounts payable to Morrison & Foerster, McCarthy Tetrault and Desjardins into notes payable
Accounts payable and cancellation premium converted into 2011 Private Placement Units
Accrued interest on Cato Holding Company note converted to note payable
Accounts payable settled in December 2011 and May/June 2012 warrant exercises
Insurance premiums settled by issuing note payable
Conversion of accrued interest and fees on February 2012 Notes into 2012 Private Placement Units
Accrued interest on July and August 2012 Notes to Platinum converted into Exchange Note
Accounts payable settled by issuance of stock or notes payable and stock
Accounts payable converted into 2012 Private Placement Units
Recognition of warrant liability upon issuance to Platinum of October 2012 Exchange Note and October 2012, February 2013 and March 2013 Investment Notes and July 2013 Convertible Note
Recognition of warrant liability for potential issuance to Platinum of Series A Exchange Warrant under the terms of the October 2012 Agreement
Statement [Table]
Statement [Line Items]
Beginning Balance, Amount
Beginning Balance, Shares
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $29,500, Amount
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $29,500, Shares
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $137,000, Amount
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $137,000, Shares
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Amount
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Shares
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $47,200, Amount
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $47,200, Shares
Proceeds allocated to warrants issued in connection with Series C preferred stock, Amount
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Amount
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Shares
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Amount
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Shares
Ending Balance, Amount
Ending Balance, Shares
Beginning Balance, Amount
Beginning Balance, Shares
Fair value of common stock issued for services, Amount
Fair value of common stock issued for services, Shares
Effect of the Merger, Amount
Effect of the Merger, Shares
Sale of common stock for cash, Amount
Sale of common stock for cash, Shares
Beneficial conversion feature on note
Fair value of warrants issued for services
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount
Common stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares
Share-based compensation expense
Forgiveness of accrued compensation and accrued interest payable to officers
Proceeds allocated to warrants issued in connection with Platinum Notes
Accrued interest on notes receivable
Proceeds allocated to warrants issued in connection with Platinum Notes and incremental fair value of warrant modification
Effect of reverse stock split
Cumulative effect of adopting new accounting standard
Common stock issued for cancellation of accounts payable and accrued interest, Amount
Common stock issued for cancellation of accounts payable and accrued interest, Shares
Incremental fair value of note conversion options from debt modification
Reclassification of warrant liability to equity
Incremental value of Platinum note modification
Incremental value of Morrison Foerster warrant modification
Stock issued in May 2011 Private Placement, net of $202,000 placement fees, Amount
Stock issued in May 2011 Private Placement, net of $202,000 placement fees, Shares
Payments on note receivable for sale of stock
Allocated proceeds from Sale of Units, amount
Allocated proceeds from Sale of Units, shares
Stock issued upon conversion of convertible promissory notes, Amount
Stock issued upon conversion of convertible promissory notes, Shares
Stock issued upon conversion of all series of preferred stock, Amount
Stock issued upon conversion of all series of preferred stock, Shares
Fair value of stock issued for services prior to the Merger, Amount
Fair value of stock issued for services prior to the Merger, Shares
Forgiveness of notes at the Merger, Amount
Stock issued upon exercise of modified warrants (includes Platinum exercises), Amount
Stock issued upon exercise of modified warrants (includes Platinum exercises), Shares
Incremental value of warrant modifications (including modification of Platinum warrants)
Fair value of bonus warrants under Discounted Warrant Exercise Program
Stock issued in Fall 2011 Follow-on Offering, Amount
Stock issued in Fall 2011 Follow-on Offering, Shares
Stock issued upon exercise of options from 1999 Stock Incentive Plan, Amount
Stock issued upon exercise of options from 1999 Stock Incentive Plan, Shares
Fair value of stock issued for services following the Merger, Amount
Fair value of stock issued for services following the Merger, Shares
Proceeds allocated to warrants issued and beneficial conversion feature in connection with 12% convertible notes
Stock issued in connection with note term extension, Amount
Stock issued in connection with note term extension, Shares
Stock issued upon conversion of Platinum Note to equity (net of Platinum warrant exercise reflected above), Amount
Stock issued upon conversion of Platinum Note to equity (net of Platinum warrant exercise reflected above), Shares
Common stock exchanged for Series A Preferred under agreements with Platinum: Common Stock Exchange Agreement, Amount
Common stock exchanged for Series A Preferred under agreements with Platinum: Common Stock Exchange Agreement, Shares
Common stock exchanged for Series A Preferred under agreements with Platinum: Note and Warrant Exchange Agreement, Amount
Common stock exchanged for Series A Preferred under agreements with Platinum: Note and Warrant Exchange Agreement, Shares
Fair value of warrants issued upon exercise of modified warrants
Fair value of shares issued in settlement of accounts payable, amount
Fair value of shares issued in settlement of accounts payable, shares
Modification of note receivable from sale of stock
Fair value of warrant issued to Cato Holding Company in connection with note payable restructure
Fair value of warrant issued to Cato Holding Company in connection with accounts payable restructure
Fair value of warrant issued to University Health Network in connection with accounts payable restructure
Fair value of warrants issued to Morrison & Foerster, Cato Reearch Ltd. and University Health Network in connection with accrued interest on underlying notes
Sale of Units in Winter 2012 Private Placement, net, Amount
Sale of Units in Winter 2012 Private Placement, net, Shares
Exchange of February 2012 convertible notes, Amount
Exchange of February 2012 convertible notes, Shares
Fair value of warrants issued to banker in connection with exchange of February 2012 convertible notes
Premium of fair value over face value of Exchange Note issued to Platinum
Fair value of Series A Exchange Warrant issuable to Platinum recorded as a Warrant Liability
Proceeds allocated to beneficial conversion feature of Investment Notes issued to Platinum in October 2012, February 2013 and March 2013
Incremental fair value of warrant modifications in Feburary 2013
Net Loss
Ending Balance, Amount
Ending Balance, Shares
Notes to Financial Statements
Description of Business
Basis of Presentation and Going Concern
Summary of Significant Accounting Policies
Fair Value Measurements
Prepaid Expenses and Other Current Assets
Property, Plant and Equipment [Abstract]
Property and Equipment
Business Combinations [Abstract]
AV-101 Acquisition
Accrued Expenses
Convertible Promissory Notes and Other Notes Payable
Capital Stock
Research and Development [Abstract]
Research and Development Expenses
Income Tax Disclosure [Abstract]
Income Taxes
Licensing and Collaborative Agreements
Text Block [Abstract]
Stock Option Plans and 401(k) Plan
Related Party Transactions
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies, Guarantees and Indemnifications
Subsequent Events
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Financial Information
Summary Of Significant Accounting Policies Policies
Basis of Presentation and Going Concern
Use of Estimates
Principles of Consolidation
Cash and Cash Equivalents
Property and Equipment
Impairment or Disposal of Long-Lived Assets
Revenue Recognition
Research and Development Expenses
Stock-Based Compensation
Income Taxes
Concentrations of Credit Risk
Warrant Liability
Comprehensive Loss
Loss per Common Share
Recent Accounting Pronouncements
Summary Of Significant Accounting Policies Tables
Computation of basic net income (loss) and diluted net loss attributable to common stockholders per share
Schedule of antidilutive securities excluded from computation of earnings per share
Fair Value Measurements Tables
Fair value heirarchy for liabilities measured at fair value on a recurring basis
Changes in Level 3 liabilities
Prepaid Expenses And Other Current Assets Tables
Prepaid Expenses
Property and equipment
Accrued Expenses Tables
Accrued Expenses
Convertible Promissory Notes And Other Notes Payable Tables
Convertible Promissory Notes and Other Notes Payable
Assumptions
Components of the discount and interest rates
Black-Scholes assumptions
Capital Stock Tables
Unit Warrant grants and allocation of Proceeds
Black-Scholes Option Pricing Model
Description of units
Shares reserved for future issuance
Provision/benefit computed for income taxes
Components of deferred tax assets
Share-based compensation expense
Black-Scholes option valuation model assumptions for share-based compensation expense
Summary of stock option plan activity
Stock options outstanding and exercisable under Company's option plan
Assets under capital lease obligations
Future minimum payments required under Capital Leases
Future minimum principal payments related to Long-Term Debt
Unaudited Quarterly Results of Operations
Description Of Business Details Narrative
NIH awarded the Company aggregate support
Merger shares
Shares outstanding at merger
Outstanding share representation
Number of shares authorized following amendment
Number of Preferred shares authorized following amendment
Series A Preferred Stock shares
Series A Preferred share par value
Conversion Rate, Series A Preferred shares
Conversion total, Series A Preferred to Common
Conversion to warrant, warrant value
Warrant exercise price
Basis Of Presentation And Going Concern Details Narrative
Accumulated Deficit during its development stage
Cash proceeds from convertible and short-term notes
Cash proceeds from grant awards and other events
Cash proceeds from Autilion purchase agreement
Equity issuance
Cash expenditure
Share purchase obligation
Share purchase obligation cash consideration
initial share issuance
Note interest rate
Warrants issued
Warrant exercise price
Private placement proceeds
Alternative financing, minimum
Alternative financing, maximum
Summary Of Significant Accounting Policies Details 1
Numerator:
less: change in fair value of warrant liability attributable to Exchange, Investment and July 2013 Warrants issued to Platinum
Net loss for diluted earnings per share attributable to common stockholders
Denominator:
Weighted average basic common shares outstanding
Assumed conversion of dilutive securities:
Warrants to purchase common stock
Potentially dilutive common shares assumed converted
Denominator for diluted earnings per share - adjusted weighted average shares
Loss per Common Share
Series A preferred stock issued and outstanding
Warrant shares issuable to Platinum upon exercise of common stock warrants by Platinum upon exchange of Series A preferred stock under the terms of the October 11, 2012 Note Purchase and Exchange Agreement
Outstanding options under the 2008 and 1999 Stock Incentive Plans
Outstanding warrants to purchase common stock
Convertible promissory notes and accrued interest
Total
Liabilities, Fair Value Disclosure
Warrant liability
Warrant liability, beginning of period
Recognition of warrant liability during period
Subsequent recognition of warrant liability during period
Mark to Market gain included in net income
Warrant liability, end of period
Prepaid Expenses And Other Current Assets Details
Prepaid Expenses
Insurance
Legal fees
Interest receivable on note receivable from sale of common stock
Technology license fees and all other
Total
Laboratory equipment
Tenant improvements
Computers and network equipment
Office furniture and equipment
Property and equipment gross
Accumulated depreciation and amortization
Series B-1 Shares issued
Series B-1 value per share
Pre-Merger purchase price
Accrued Expenses Details
Accrued Expenses
Accrued professional services
Accrued compensation
Accrued royalties and license fees
All other
Total
Principal Balance
Accrued Interest
Total
Note discount on principal
Note discount on accrued interest
Note discount, total
Face value
Discount attributable to fair value of the warrant
Discount attributable to beneficial conversion feature
Inception date carrying value
Effective Interest Rate
Market price of common stock
Exercise price
Risk-free interest rate
Volatility
Term (years)
Dividend rate
Fair value per share
Number of shares
Fair value at date of issuance
Market price per share
Exercise price per share
Expected term (years)
Fair Value per share
Investment, Name [Axis]
Fair value warrant
Decrease in fair value warrant quarter end
Decrease in fair value warrant three months end
Market price per share
Exercise price per share
Risk-free interest rate
Expected term (years)
Volatility
Dividend rate
Change in warrant put and note extension option and warrant liabilities
Interest rate
Gross proceeds
Accrued interest rate per share
Warrants to purchase shares
Investment Warrant exercise price
Market price per share
Exercise price per share
Fair Value per share
Warrants outstanding
Exercise price per share
Expirate date range
Weighted average years to expiration
Shares subject to purchase
Capital Stock Details 2
Upon exchange of all shares of Series A Preferred Stock currently issued and outstanding
Warrant shares issuable to Platinum upon exercise of common stock warrant upon exchange of Series A preferred stock under the terms of the October 11, 2012 Note Purchase and Exchange Agreement
110% of shares issuable upon conversion of 10% convertible Exchange Note and Investment Notes issued to Platinum in October 2012, February 2013 and March 2013, including interest accrued through maturity (2)
Pursuant to warrants to purchase common stock:
Subject to outstanding warrants
Issuable pursuant to accrued interest through maturity on outstanding promissory notes issued to Morrison & Foerster, Cato Research Ltd., and University Health Network
Pursuant to warrants to purchase common stock, total
Pursuant to stock incentive plans:
Subject to outstanding options under the 2008 and 1999 Stock Incentive Plans
Available for future grants
Pursuant to stock incentive plans, total
Upon conversion of notes and accrued interest issued pursuant to the Winter 2013/2014 Private Placement of Units
Upon further sales of Units pursuant to the 2012 Private Placement of Units
Upon further sale of shares to Autilion under the amended Securities Purchase Agreement
Total
Purchase obligation
Purchase obligation, per share price
Purchase obligation, aggregate cash consideration
Initial closing of financing
Initial issuance of shares under puchase agreement
Note issued
Note conversion price
Warrant issued
Repayment of previous advances to officers
Restricted common stock
Exercise price
Exercise price at grant date
Probability of issuance
Exercised warrants
Cash proceeds from exercise of warrants
Modified warrants exercised
Noncash share compensation paid for professional services
Research and development expenses
Income Taxes Details
Computed expected tax benefit
Tax effect of Warrant Liabilitiy mark to market
Losses not benefitted
Other
Income tax expense
Income Taxes Details 1
Net operating loss carry-forwards
Basis differences in fixed assets
Accruals and reserves
Total deferred tax assets, net
Valuation allowance
Net deferred tax asset
Valuation allowance increase
U.S. federal net operating loss carryforwards
state net operating loss carryforwards
Monthly research funding payments
Promissory note issuance
Warrant issued with promissory note
Research funding payments
Award upon agreed milestones
Grant revenue
Research and development expenses
Stock Option Plans And 401K Plan Details
Research and development expense:
Stock option grants, including expense related to modifications
Warrants granted to officer in March 2014
Warrants granted to officer in March 2013
Total research and development expense related to stock-based compensation expense
General and administrative expense:
Stock option grants, including expense related to modifications
Warrants granted to officer and directors in March 2014
Warrants granted to officers and directors in March 2013
Total General and administrative expense related to stock-based compensation expense
Total stock-based compensation expense
Expected dividend yield
Exercise price
Market price on date of grant
Risk-free interest rate
Expected (years)
Volatility
Fair value per share at grant date
Number of Shares
Options outstanding at beginning of period
Options granted
Options exercised
Options cancelled
Options forfeited
Options expired
Options outstanding at end of period
Options exercisable at end of period
Weighted Average Exercise Price
Weighted average exercise price, Options outstanding at beginning of period
Options granted
Options exercised
Options cancelled
Options forfeited
Options expired
Weighted average exercise price, Options outstanding at end of period
Weighted average exercise price, Options exercisable at end of period
Weighted average grant-date fair value of options granted during the period
Option exercise price
Weighted Average Remaining Years until Expiration
ShareBasedCompensationAxis [Axis]
Maximum number of shares granted
Maximum term of 10% or more owners
Maximum term of any other owner
Cancelled options
New options granted to cancelled holders
Exercise price to new options granted
Modification options granted
Modification charge
Shares with reduced exercise price
Modification charge of options to certain employees
Shares remaining for grant under 2008 Plan
Quoted market price of common stock
Aggregate intrinsic value of outstanding options
Aggregate intrinsic value related to exercisable options
Unrecognized compensation cost
Unrecognized compensation cost related to unvested warrant grants
Proceeds from short-term loan
Interest rate on note
Total interest expense
Incurred expenses on research and subsequent other projects
Estimate accrued of gross-up amount
Commitments Contingencies Guarantees And Indemnifications Details
Capital lease obligations
Leased laboratory equipment
Leased office equipment
Total lease obligations
Accumulated amortization
Leased laboratory and computer equipment, net
Commitments Contingencies Guarantees And Indemnifications Details 1
Future minimum payment, capital leases, Equipment
Lease payment 2015
Lease payment 2016
Lease payment 2017
Lease payment 2018
Future minimum lease payments
Less imputed interest included in minimum lease payments
Present value of minimum lease payments
Less current portion
Non-current capital lease obligation
Commitments Contingencies Guarantees And Indemnifications Details 2
Future minimum payments, principal
2015
2016
2017
2018
Total
Commitments Contingencies Guarantees And Indemnifications Details 3
Future minimum principal payments related to long-term debt:
2015
2016
2017
2018
Thereafter through June 2019
Total
Facility rent expense
Subsequent Events Details Narrative
Note issued
Interest rate
Shares issued
Exercise price
Technology promissory note
Restricted shares of common stock issued, technology promissory note
License maintenance fees and reimbursable patent prosecution costs
2013 Unit Notes aggregate face amount
2013 Unit Notes paid amount
Gross proceeds
Supplemental Financial Information Details
Total revenues
Research and development
Total operating expenses
Loss from operations
Change in warrant liabilities
Other income
Income (loss) before income taxes
Income taxes
Net income (loss)
Basic net income (loss) per common share
Diluted net loss per common share
Weighted average shares used in computing:
Basic net income (loss) per common share
Diluted net loss per common share
Shares of common stock retroactively reflected as outstanding
Shares held by stockholders, pre-merger
Custom Element
Additional Investor Relations Services Member.
Blackscholes Option Pricing Model Table Text Block.
Custom Element.
Custom element.
Cato Holding Company Member.
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element.
Desjardins Member.
Custom Element
Custom Element
Custom Element
Custom Element
Custom element.
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
February 2012 Convertible Notes 12 Percent Member.
Foregoing Exercises Member.
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Investor Relation Services Member.
Investor Relations And Public Company Services Member.
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Legal Fees1.
Custom Element
Custom Element
Market Price Per Share.
Custom Element.
Custom Element.
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Notes Payable Discount.
Notes Payable Discount Related Parties.
Custom Element.
Custom Element
Outstanding Shares.
Outstanding Warrants To Purchase Common Stock.
Custom Element
Platinum Member.
Custom element.
Post Modification Warrants Member.
Custom element.
Pre Modification Warrants Member.
Custom Element
Custom Element
Custom Element
Custom Element
Prepaid Expenses TableText Block.
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Qualified Financing Member.
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element.
Share Based Compensation Warrants Eight Member.
Share Based Compensation Warrants Eleven Member.
Share Based Compensation Warrants Five Member.
Share Based Compensation Warrants Four Member.
Share Based Compensation Warrants Nine Member.
Share Based Compensation Warrants One Member.
Share Based Compensation Warrants Seven Member.
Share Based Compensation Warrants Six Member.
Share Based Compensation Warrants Ten Member.
Share Based Compensation Warrants Twelve Member.
Share Based Compensation Warrants Two Member.
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Custom Element
Total.
Unrelated Parties Member.
Warrant exercise price.
Warrant Modifications Member.
WarrantsExercisePrice.
Price.721.80Member
SeniorNoteSixMember
Assets, Current
Assets
Liabilities, Current
Capital Lease Obligations, Noncurrent
Liabilities, Noncurrent
Liabilities
Treasury Stock, Value
Stockholders' Equity Attributable to Parent
Liabilities and Equity
ChangeInPutAndNoteExtensionOptionAndWarrantLiabilities
LossOnEarlyExtinguishmentOfDebt
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Deposit Assets
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Machinery and Equipment
Net Cash Provided by (Used in) Investing Activities
Net Cash Provided by (Used in) Financing Activities
Cash and Cash Equivalents, Period Increase (Decrease)
Capital Lease Obligations Incurred
StockholdersEquityForPreferredStock
SharesIssuedForPreferredStock
Shares, Issued
Basis of Accounting, Policy [Policy Text Block]
Property, Plant and Equipment, Policy [Policy Text Block]
Research and Development Expense, Policy [Policy Text Block]
Income Tax, Policy [Policy Text Block]
Schedule of Accrued Liabilities [Table Text Block]
Schedule of Debt [Table Text Block]
ScheduleofSharebasedCompensationExpenseTextBlock
WarrantExercisePrice
Earnings Per Share [Abstract]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value
Prepaid Expense, Current [Abstract]
Prepaid Expense and Other Assets, Current
Accrued Liabilities, Current [Abstract]
Long-term Debt, Gross
Fair Value Assumptions, Exercise Price
Long-Duration Contracts, Assumptions by Product and Guarantee, Volatility Rate
DividendRate
Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
Common Stock, Capital Shares Reserved for Future Issuance
EffectiveIncomeTaxRateReconciliationOther
Chemicals Revenue
RelatedToStockOptionGrantsIncludingExpenserelatedToModifications
Temporary Equity, Redemption Price Per Share
FairValueAssumptionsRiskFreeInterestRates
ShareBasedCompensationArrangementByShareBasedPaymentAwardVolatilityRate
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice2
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Capital Lease Obligations [Abstract]
FutureMinimumPrincipalPayments
Long-term Debt, Maturities, Repayments of Principal in Next Rolling Twelve Months
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four
Long-term Debt
OtherIncomeLoss